Literature DB >> 11284379

Quality-of-life assessment in comparative therapeutic trials and causal structure considerations in peripheral occlusive arterial disease.

P Lehert1.   

Abstract

When considering the use of quality of life as a primary end-point in phase III to IV comparative trials, the trial designer generally faces some unresolved questions. These include: How does one explain that some dimensions [quality-of-life (QOL) instruments usually have more than 1 dimension] are directly influenced by the studied treatments whereas others are not? How can one interpret conflicting results between conventional clinical measurements and QOL measurements, when the relationships between conventional clinical measurement and quality of life are not known? In this paper, we consider the use of Structural Equation Modelling (SEM) as a methodological alternative to answer these problems. As an example, we analyse the internal causal structure of the Claudication Scale (CLAU-S), a specific QOL 5-dimensional instrument for peripheral occlusive arterial disease. In applying SEM to different studies and different types of calculation, we suggest that CLAU-S is based on a stable, simple and comprehensive QOL model, is compatible with the general International Classification of Impairments, Disabilities and Handicaps (ICIDH) classification, is coherent and complementary with clinical data measurements and, using differences in a prospective study, considerably improves specificity. We suggest that SEM can help in QOL scale validation, in providing a unified scheme of the inter-relationships between internal dimensions and with external variables, in particular, clinical measurements.

Entities:  

Mesh:

Year:  2001        PMID: 11284379     DOI: 10.2165/00019053-200119020-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  14 in total

1.  Relationship between physical activity recall and free-living daily physical activity in older claudicants.

Authors:  R B Otis; A S Brown; C J Womack; T Fonong; A W Gardner
Journal:  Angiology       Date:  2000-03       Impact factor: 3.619

Review 2.  Structural equation models in medical research.

Authors:  P M Bentler; J A Stein
Journal:  Stat Methods Med Res       Date:  1992       Impact factor: 3.021

Review 3.  Measuring quality of life in clinical trials: a taxonomy and review.

Authors:  G H Guyatt; S J Veldhuyzen Van Zanten; D H Feeny; D L Patrick
Journal:  CMAJ       Date:  1989-06-15       Impact factor: 8.262

4.  Effect of propionyl-L-carnitine on quality of life in intermittent claudication.

Authors:  G Brevetti; S Perna; C Sabba; V D Martone; A Di Iorio; G Barletta
Journal:  Am J Cardiol       Date:  1997-03-15       Impact factor: 2.778

5.  [Intermittent claudication and quality of life. Psychometric validation of the French version of the CLAU-S questionnaire].

Authors:  H Boccalon; P Lehert; S Comte
Journal:  J Mal Vasc       Date:  2000-04

6.  Improvement in the quality of life after i.v. PGE1 therapy for intermittent claudication.

Authors:  A Creutzig; M Bullinger; M Cachovan; C Diehm; H T Forst; J D Gruss; S Horsch; W Rogatti; P Scheffler; F Spengel; H Stiegler
Journal:  Vasa       Date:  1997-05       Impact factor: 1.961

7.  Quality of life following percutaneous transluminal angioplasty for claudication.

Authors:  T A Cook; M O'Regan; R B Galland
Journal:  Eur J Vasc Endovasc Surg       Date:  1996-02       Impact factor: 7.069

8.  Subjective health of patients with peripheral vascular disease.

Authors:  S M Hunt; J McEwen; S P McKenna; E M Backett; C U Pope
Journal:  Practitioner       Date:  1982-01

9.  Quality of life analysis in patients with lower limb ischaemia: suggestions for European standardisation.

Authors:  I C Chetter; J I Spark; P Dolan; D J Scott; R C Kester
Journal:  Eur J Vasc Endovasc Surg       Date:  1997-06       Impact factor: 7.069

10.  On statistical characteristics of quality of life assessment.

Authors:  S C Chow; F Y Ki
Journal:  J Biopharm Stat       Date:  1994-03       Impact factor: 1.051

View more
  1 in total

1.  International validation of the CLAU-S quality-of-life questionnaire for use in patients with intermittent claudication.

Authors:  P Marquis; S Comte; P Lehert
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.